MATE Family Transporter Proteins for Organic Cation Excretion

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

The identity and function of the specific transporter proteins responsible for the final stage of organic cation excretion in mammals remain unknown, despite the recognition of a putative multidrug recognizing excretion transporter, hindering the development of effective assays and technologies for drug and waste excretion.

Innovation Solution

Development of an assay system and lipid membrane composition containing polypeptides with specific amino acid sequences, such as SEQ ID NO: 2, 4, 6, or 22, or their variants, to identify and utilize MATE family proteins as transporters for organic cations, including the use of liposomes and transformants to test chemical nephrotoxicity and hepatotoxicity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Device complexity

If homologues of known kidney transporters are searched to identify the molecular entity of OC transporters, then the search scope is narrowed down, but no molecule showing the intended function has been identified yet

Engineering Contradiction:
Improvesearch complexityVSAvoididentification success
Core Design Contradiction:
Device complexityVSReliability

Solution Approach 1:

Instead of searching for mammalian homologues of known kidney transporters (conventional approach), the inventors inverted the approach by searching for mammalian orthologues of bacterial multidrug efflux pumps (MATE family). This reverse strategy led to the discovery of MATE1 and MATE2-K as the molecular entities responsible for organic cation excretion, resolving the identification failure of the conventional approach

Inventive Principle:
Principle #13The other way round (Inversion)

2Productivity

If an assay system is developed using identified transporter proteins, then drug and waste excretion can be effectively assessed, but the molecular entity of OC transporters remained unknown for a long time

Engineering Contradiction:
Improveexcretion assessment efficiencyVSAvoidtime for molecular identification
Core Design Contradiction:
ProductivityVSLoss of time

Solution Approach 1:

The inventors performed preliminary action by first identifying the molecular entities (MATE1 and MATE2-K) through database searching and sequence analysis before developing the functional assay system. This preliminary identification of target molecules enabled the subsequent development of effective assays for drug and waste excretion, avoiding the time loss that would have occurred if assays were developed without known targets

Inventive Principle:
Principle #10Preliminary action

3Adaptability or versatility

If the entity of transporters remains unknown, then further research and application development are hindered, but searching databases from unique viewpoints is required

Engineering Contradiction:
Improveresearch flexibilityVSAvoidtransporter identification difficulty
Core Design Contradiction:
Adaptability or versatilityVSDifficulty of detecting and measuring

Solution Approach 1:

The inventors applied the universality principle by recognizing that the MATE family proteins in mammals share functional characteristics with bacterial multidrug efflux pumps despite sequence divergence. This universal functional approach allowed identification of MATE1 and MATE2-K as multifunctional transporters handling various organic cations, drugs, and waste products, overcoming the difficulty of detection through functional rather than sequence-based identification

Inventive Principle:
Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The system effectively identifies and utilizes MATE family proteins for the excretion of organic cations, providing a method to assess chemical toxicity and regulate substance transport across cell membranes, thereby improving the understanding and management of drug and waste excretion processes.

Implementation Method 1

a polypeptide... having a transporter activity in a cell membrane

Methodology Applied
Scientific EffectExchange transport:

Implementation Method 2

mediates exchange transport of electroneutral protons and OCs

Methodology Applied
Scientific EffectProton-cation exchange:

Implementation Method 3

Organic compounds having toxicity are taken up from membrane of the renal tubules cells on the vascular side and excreted from the brush border membrane side

Methodology Applied
Scientific EffectMembrane transport:

Implementation Method 4

utilization of the same... to test chemical nephrotoxicity and hepatotoxicity

Methodology Applied
Scientific EffectTransporter activity assay:

Data Source

PatentUS7892728B2Transporter protein in mammal and utilization of the same
Publication Date: 2011.02.22 GENOMEMBRANE
  • US7892728B2 patent drawing
  • US7892728B2 patent drawing
  • US7892728B2 patent drawing

AI summary

The present invention provides a lipid membrane that contains a polypeptide consisting of the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, or 22. Use of the present invention enables screening for a chemical which regulates excretion of a chemical and/or a waste. Furthermore, use of the present invention enables an arbitrary chemical to be tested for nephrotoxicity and/or hepatotoxicity.